← Leaderboards
Dana E. Austin
Serpin Pharma, Llc
$732,034
Attributed
$1,464,067
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $838.7K · FY2024–25$1M$750K$500K$250K$0
'24
'25
Funding mix
By agency
NIH$1,464,067 · 1
By mechanism
R44$1,464,067 · 1
Top collaborators
- Cohava Gelber2 shared
Others in their field
Other Rising Stars on “Advanced Development”
- Kiran Datta · Leidos Biomedical Research, Inc.$277,585,346
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Mari Ostendorf · University Of Washington$51,931,230
- Richard Smith · Medical Device Innovation Consortium$41,401,350
- Brian Zavertnik · Palantir Technologies, Inc.$33,059,912
- Cyrus Wadia · Activate Global, Inc.$31,489,493
Research focus
Advanced DevelopmentAdverse EffectsAffectAgonistAnalgesicsAnalytical MethodAntibodiesAnticancer ActivityAnti-Inflammatory AgentsAppropriate DoseBiological AvailabilityBone MarrowBreastBreast Cancer PatientCancer PatientCancer SurvivalCancer SurvivorCell ModelCellsChemotherapyChemotherapy-Induced Peripheral NeuropathyChinese HamsterChromosome AbnormalityAcute